Which of the following tumors is indicated by elevated Beta2-microglobulin and has a good prognosis?

Elevated Beta2-microglobulin levels are commonly associated with multiple myeloma, a plasma cell neoplasm characterized by the proliferation of abnormal plasma cells in the bone marrow. In multiple myeloma, Beta2-microglobulin can serve as both a diagnostic and prognostic marker.

A key feature of multiple myeloma is the production of excessive monoclonal immunoglobulins, and Beta2-microglobulin is a component of the major histocompatibility complex (MHC) class I molecules. High levels of this protein in the blood can correlate with tumor burden and overall disease severity in patients.

In terms of prognosis, while elevated levels of Beta2-microglobulin generally indicate a worse outcome, the context of this question may be referring to specific patient scenarios where, despite the elevated levels, patients may achieve a favorable response to treatment and long-term survival. However, it is essential to note that different studies present varying prognostic significance based on therapeutic strategies, which can sometimes lead to a good prognosis despite elevated levels.

Other tumors listed, such as ovarian cancer, small cell lung carcinoma, and pancreatic cancer, are associated with distinct biomarkers that do not include Beta2-microglobulin as prominently.